Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker.Please watch the video ...

The disruptive elements of the U.S. Stargate program and the release of the Chinese artificial-intelligence company DeepSeek has put more critical eyes than ever on major AI players like Microsoft ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.

Apple iPhone Sales Shrink Slightly as Investors Await AI Payoff The company has heavily advertised AI features since the latest iPhones were released in September. Amazon Raises Its Ad Spending on ...